Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.
Identifieur interne : 000864 ( Main/Exploration ); précédent : 000863; suivant : 000865Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.
Auteurs : Rashmi Ranjan Das [Inde] ; Bijayini Behera [Inde] ; Baijayantimala Mishra [Inde] ; Sushree Samiksha Naik [Inde]Source :
- Indian journal of medical microbiology [ 1998-3646 ]
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Azithromycine (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Chloroquine (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux).
- MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antipaludiques, Antiviraux, Azithromycine, Chloroquine, Hydroxychloroquine.
- Adolescent, Adulte, Humains, Pandémies.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (drug effects), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Antimalarials, Antiviral Agents, Azithromycin, Chloroquine, Hydroxychloroquine.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Adolescent, Adult, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
As anti-malarial drugs have been found to inhibit Corona viruses in vitro, studies have evaluated the effect of these drugs inCOVID-19 infection. We conducted an updated meta-analysis of clinical trials and observational studies published till June 2020. Patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) infection were included. The drugs used in the intervention group are Chloroquine (CQ)/Hydroxychloroquine (HCQ) with or without Azithromycin. The primary outcome is time to achieve virological cure. Of 1040 citations, 11 studies provided data of 1215 patients. Compared to control, CQ/HCQ has no significant effect on the time to negative COVID-19 RT-PCR results, neither in clinical trials (mean difference [MD] 1.55; 95% confidence interval [CI] - 0.7 to 3.79; P = 0.18; n = 180), nor in observational studies (MD 1.14; 95%CI - 11.98 to 14.26; P = 0.86, n = 407). CQ/HCQ did not affect the virological cure after day 3, 7, 10, 14, 21 and 28; except after day 5, as shown by a single small non-randomised trial (odds ratio [OR] 9.33; 95% CI 1.51 to 57.65; P = 0.02, n = 30). Pooled data from 2 observational studies showed a significant effect of CQ/HCQ on virological cure by after day 10 (OR 7.86; 95% CI 4.4 to 14.04, P < 0.001, n = 373) and day 14 (OR 6.37; 95% CI 3.01 to 13.48, P < 0.001, n = 407). The GRADE evidence generated was of "very low-quality/certainty". To conclude, CQ/HCQ does not affect the time to virological cure compared to usual/standard of care in COVID-19 infection. Recurrent infection in a smaller number of patients was noted in the CQ/HCQ group. As the evidence generated was of "very low-quality/certainty)", large good quality studies are needed to confirm the present findings.
DOI: 10.4103/ijmm.IJMM_20_330
PubMed: 33154234
PubMed Central: PMC7709583
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.</title><author><name sortKey="Das, Rashmi Ranjan" sort="Das, Rashmi Ranjan" uniqKey="Das R" first="Rashmi Ranjan" last="Das">Rashmi Ranjan Das</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Behera, Bijayini" sort="Behera, Bijayini" uniqKey="Behera B" first="Bijayini" last="Behera">Bijayini Behera</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Baijayantimala" sort="Mishra, Baijayantimala" uniqKey="Mishra B" first="Baijayantimala" last="Mishra">Baijayantimala Mishra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Naik, Sushree Samiksha" sort="Naik, Sushree Samiksha" uniqKey="Naik S" first="Sushree Samiksha" last="Naik">Sushree Samiksha Naik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jul-Dec</date><idno type="RBID">pubmed:33154234</idno><idno type="pmid">33154234</idno><idno type="doi">10.4103/ijmm.IJMM_20_330</idno><idno type="pmc">PMC7709583</idno><idno type="wicri:Area/Main/Corpus">000885</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000885</idno><idno type="wicri:Area/Main/Curation">000885</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000885</idno><idno type="wicri:Area/Main/Exploration">000885</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.</title><author><name sortKey="Das, Rashmi Ranjan" sort="Das, Rashmi Ranjan" uniqKey="Das R" first="Rashmi Ranjan" last="Das">Rashmi Ranjan Das</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Behera, Bijayini" sort="Behera, Bijayini" uniqKey="Behera B" first="Bijayini" last="Behera">Bijayini Behera</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Mishra, Baijayantimala" sort="Mishra, Baijayantimala" uniqKey="Mishra B" first="Baijayantimala" last="Mishra">Baijayantimala Mishra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author><author><name sortKey="Naik, Sushree Samiksha" sort="Naik, Sushree Samiksha" uniqKey="Naik S" first="Sushree Samiksha" last="Naik">Sushree Samiksha Naik</name><affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, Odisha, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, Odisha</wicri:regionArea><wicri:noRegion>Odisha</wicri:noRegion></affiliation></author></analytic><series><title level="j">Indian journal of medical microbiology</title><idno type="eISSN">1998-3646</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>COVID-19 (MeSH)</term><term>Chloroquine (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Chloroquine (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term><term>Antiviraux</term><term>Azithromycine</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As anti-malarial drugs have been found to inhibit Corona viruses in vitro, studies have evaluated the effect of these drugs inCOVID-19 infection. We conducted an updated meta-analysis of clinical trials and observational studies published till June 2020. Patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) infection were included. The drugs used in the intervention group are Chloroquine (CQ)/Hydroxychloroquine (HCQ) with or without Azithromycin. The primary outcome is time to achieve virological cure. Of 1040 citations, 11 studies provided data of 1215 patients. Compared to control, CQ/HCQ has no significant effect on the time to negative COVID-19 RT-PCR results, neither in clinical trials (mean difference [MD] 1.55; 95% confidence interval [CI] - 0.7 to 3.79; P = 0.18; n = 180), nor in observational studies (MD 1.14; 95%CI - 11.98 to 14.26; P = 0.86, n = 407). CQ/HCQ did not affect the virological cure after day 3, 7, 10, 14, 21 and 28; except after day 5, as shown by a single small non-randomised trial (odds ratio [OR] 9.33; 95% CI 1.51 to 57.65; P = 0.02, n = 30). Pooled data from 2 observational studies showed a significant effect of CQ/HCQ on virological cure by after day 10 (OR 7.86; 95% CI 4.4 to 14.04, P < 0.001, n = 373) and day 14 (OR 6.37; 95% CI 3.01 to 13.48, P < 0.001, n = 407). The GRADE evidence generated was of "very low-quality/certainty". To conclude, CQ/HCQ does not affect the time to virological cure compared to usual/standard of care in COVID-19 infection. Recurrent infection in a smaller number of patients was noted in the CQ/HCQ group. As the evidence generated was of "very low-quality/certainty)", large good quality studies are needed to confirm the present findings.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33154234</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1998-3646</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3 & 4</Issue><PubDate><MedlineDate>2020 Jul-Dec</MedlineDate></PubDate></JournalIssue><Title>Indian journal of medical microbiology</Title><ISOAbbreviation>Indian J Med Microbiol</ISOAbbreviation></Journal><ArticleTitle>Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.</ArticleTitle><Pagination><MedlinePgn>265-272</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijmm.IJMM_20_330</ELocationID><Abstract><AbstractText>As anti-malarial drugs have been found to inhibit Corona viruses in vitro, studies have evaluated the effect of these drugs inCOVID-19 infection. We conducted an updated meta-analysis of clinical trials and observational studies published till June 2020. Patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) infection were included. The drugs used in the intervention group are Chloroquine (CQ)/Hydroxychloroquine (HCQ) with or without Azithromycin. The primary outcome is time to achieve virological cure. Of 1040 citations, 11 studies provided data of 1215 patients. Compared to control, CQ/HCQ has no significant effect on the time to negative COVID-19 RT-PCR results, neither in clinical trials (mean difference [MD] 1.55; 95% confidence interval [CI] - 0.7 to 3.79; P = 0.18; n = 180), nor in observational studies (MD 1.14; 95%CI - 11.98 to 14.26; P = 0.86, n = 407). CQ/HCQ did not affect the virological cure after day 3, 7, 10, 14, 21 and 28; except after day 5, as shown by a single small non-randomised trial (odds ratio [OR] 9.33; 95% CI 1.51 to 57.65; P = 0.02, n = 30). Pooled data from 2 observational studies showed a significant effect of CQ/HCQ on virological cure by after day 10 (OR 7.86; 95% CI 4.4 to 14.04, P < 0.001, n = 373) and day 14 (OR 6.37; 95% CI 3.01 to 13.48, P < 0.001, n = 407). The GRADE evidence generated was of "very low-quality/certainty". To conclude, CQ/HCQ does not affect the time to virological cure compared to usual/standard of care in COVID-19 infection. Recurrent infection in a smaller number of patients was noted in the CQ/HCQ group. As the evidence generated was of "very low-quality/certainty)", large good quality studies are needed to confirm the present findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Rashmi Ranjan</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behera</LastName><ForeName>Bijayini</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Baijayantimala</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Microbiology, AIIMS, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naik</LastName><ForeName>Sushree Samiksha</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Capital Hospital, Bhubaneswar, Odisha, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Indian J Med Microbiol</MedlineTA><NlmUniqueID>8700903</NlmUniqueID><ISSNLinking>0255-0857</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aminoquinoline</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">evidence-based medicine</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33154234</ArticleId><ArticleId IdType="pii">IndianJMedMicrobiol_2020_38_3_265_299836</ArticleId><ArticleId IdType="doi">10.4103/ijmm.IJMM_20_330</ArticleId><ArticleId IdType="pmc">PMC7709583</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine (Baltimore). 2020 Dec 24;99(52):e23720</Citation><ArticleIdList><ArticleId IdType="pubmed">33350752</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):776-785</Citation><ArticleIdList><ArticleId IdType="pubmed">32297988</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 Apr 15;48(8):1003-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19281331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Cell Biol. 2020 May 18;12(4):322-325</Citation><ArticleIdList><ArticleId IdType="pubmed">32236562</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105945</Citation><ArticleIdList><ArticleId IdType="pubmed">32194152</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Oct 18;343:d5928</Citation><ArticleIdList><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>BJGP Open. 2020 Jun 23;4(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32265182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation><ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Math Stat Psychol. 2009 Feb;62(Pt 1):97-128</Citation><ArticleIdList><ArticleId IdType="pubmed">18001516</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Med (Lausanne). 2020 Jul 29;7:482</Citation><ArticleIdList><ArticleId IdType="pubmed">32850924</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosurg Focus. 2015 Mar;38(3):E12</Citation><ArticleIdList><ArticleId IdType="pubmed">25727221</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2016 Oct 12;355:i4919</Citation><ArticleIdList><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceuticals (Basel). 2020 May 14;13(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">32423024</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Das, Rashmi Ranjan" sort="Das, Rashmi Ranjan" uniqKey="Das R" first="Rashmi Ranjan" last="Das">Rashmi Ranjan Das</name></noRegion><name sortKey="Behera, Bijayini" sort="Behera, Bijayini" uniqKey="Behera B" first="Bijayini" last="Behera">Bijayini Behera</name><name sortKey="Mishra, Baijayantimala" sort="Mishra, Baijayantimala" uniqKey="Mishra B" first="Baijayantimala" last="Mishra">Baijayantimala Mishra</name><name sortKey="Naik, Sushree Samiksha" sort="Naik, Sushree Samiksha" uniqKey="Naik S" first="Sushree Samiksha" last="Naik">Sushree Samiksha Naik</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000864 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000864 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33154234
|texte= Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33154234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |